

Search Results -

Term	Documents
LM609.USPT.	33
LM609S	
TUMOR\$	
TUMOR.USPT.	31014
TUMORACTIVITY.USPT.	
TUMORAL.USPT.	556
TUMORALALPHA.USPT.	1
TUMORALE.USPT.	3
TUMORALITY.USPT.	1
TUMORALLY.USPT.	24
(LM609 AND (TUMOR\$ OR TUMOUR\$ OR CANCER\$ OR METASTASIS OR ANGIOGENESIS)).USPT.	33
There are more results than shown above. Click here to view the e	ntire set.

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index

IBM Technical Disclosure Bulletins

Database:

Refine Search: lm609 and (tumor\$ or tumour\$ or cancer\$ or metastasis or angiogenesis) Clear

Search History

Today's Date: 4/8/2001

USPT lm609 and (tumor\$ or tumour\$ or cancer\$ or metastasis or angiogenesis)

Hit Count Set Name

33 L1

Collections Definition, Editing, Browsing

Name:	Undefined
Contents:	5981478 ▲
Comment:	
Database:	US Patents Full-Text Database US Patents Pre-Grant Publication Full-Text Database JPO Abstracts Database EPO Abstracts Database Derwent World Patents Index IBM Technical Disclosure Bulletins
S	ave Save As Help Reset Quit Search Get Images Classification Info
	Main Menu Collection Directory

s s5 and 1m609 316 S5 210 LM609 9 S5 AND LM609 S9 ? t s9/3/all . (Item 1 from file: 5) DIALOG(R)File 5:Biosis Previews(R) (c) 2001 BIOSIS. All rts. reserv. BIOSIS NO.: 200000370041 Hypoxia induces differential expression of the integrin receptors alphavbeta3 and alphavbeta5 in cultured human endothelial cells. AUTHOR: Walton Harry L; Corjay Martha H; Mohamed Seema N; Mousa Shaker A; Santomenna Linda D; Reilly Thomas M(a) AUTHOR ADDRESS: (a) Cardiovascular Diseases Research, DuPont Pharmaceuticals Company, Wilmington, DE, 19880-0400**USA JOURNAL: Journal of Cellular Biochemistry 78 (4):p674-680 12 June, 2000 MEDIUM: print ISSN: 0730-2312 DOCUMENT TYPE: Article RECORD TYPE: Abstract LANGUAGE: English SUMMARY LANGUAGE: English (Item 2 from file: 5) DIALOG(R)File 5:Biosis Previews(R) (c) 2001 BIOSIS. All rts. reserv. BIOSIS NO.: 199800259444 Detection of tumor angiogenesis in vivo by alphavbeta3-targeted magnetic resonance imaging. AUTHOR: Sipkins Dorothy A(a); Cheresh David A; Kazemi Mahmood R; Nevin Linda M; Bednarski Mark D; Li King C P AUTHOR ADDRESS: (a) Lucas MRS Res. Cent., Dep. Radiol., Stanford Univ. Sch. Med., Stanford, CA 94305**USA JOURNAL: Nature Medicine 4 (5):p623-626 May, 1998 ISSN: 1078-8956 DOCUMENT TYPE: Article RECORD TYPE: Abstract LANGUAGE: English (Item 3 from file: 5) DIALOG(R) File 5: Biosis Previews(R) (c) 2001 BIOSIS. All rts. reserv. BIOSIS NO.: 199799552054 Immunohistochemical analysis of integrin alpha-v-beta-3 expression on tumor-associated vessels of human carcinomas. AUTHOR: Max Regina; Gerritsen Roland R C M; Nooijen Peet T G A; Goodman

Simon L; Sutter Arne; Keilholz Ulrich; Ruiter Dirk J; De Waal Robert M W

AUTHOR ADDRESS: (a) Dep. Pathol., Univ. Hosp. Nijmegen, P.O. Box 9101, 6500

JOURNAL: International Journal of Cancer 71 (3):p320-324 1997

(a)

HB Nijmegen**Netherlands

ISSN: 0020-7136 RECORD TYPE: Abstract LANGUAGE: English

9/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

10064065 BIOSIS NO.: 199598518983

Antiintegrin alpha-v-beta-3 blocks human breast

cancer growth and angiogenesis in human skin.

AUTHOR: Brooks Peter C(a); Stromblad Staffan; Klemke Richard; Visscher

Daniel; Sarkar Fazlul H; Cheresh David A

AUTHOR ADDRESS: (a) Dep. Immunol. Vascular Biol., Scripps Research Inst.,

10666 North Torrey Pines Road, La Jolla, C**USA

JOURNAL: Journal of Clinical Investigation 96 (4):p1815-1822 1995

ISSN: 0021-9738

DOCUMENT TYPE: Article RECORD TYPE: Abstract LANGUAGE: English

9/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

09948697 BIOSIS NO.: 199598403615

An antagonist of integrin alpha-v-beta-3 prevents

maturation of blood vessels during embryonic neovascularization. AUTHOR: Drake Christopher J; Cheresh David A; Little Charles D(a)

AUTHOR ADDRESS: (a) Dep. Cell Biol., Cardiovascular Dev. Biol. Cent., Med.

Univ. South Carolina, 171 Ashley Ave., Ch**USA

JOURNAL: Journal of Cell Science 108 (7):p2655-2661 1995

ISSN: 0021-9533

DOCUMENT TYPE: Article RECORD TYPE: Abstract LANGUAGE: English

9/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

09795582 BIOSIS NO.: 199598250500

An antibody to the integrin alpha-v-beta-3 inhibits

ocular angiogenesis.

AUTHOR: Friedlander M; Shaffer R; Kincaid C; Brooks P; Cheresh D AUTHOR ADDRESS: Dep. Cell Biology, Scripps Res. Inst., La Jolla, CA**USA JOURNAL: Investigative Ophthalmology & Visual Science 36 (4):pS1047 1995 CONFERENCE/MEETING: Annual Meeting of the Investigative Ophthalmology and Visual Science Fort Lauderdale, Florida, USA May 14-19, 1995

ISSN: 0146-0404

RECORD TYPE: Citation LANGUAGE: English

9/3/7 (Item 1 from file: 73)

DIALOG(R) File 73: EMBASE

(c) 2001 Elsevier Science B.V. All rts. reserv.

06873254 EMBASE No: 1997157582

Cytokine treatment of endothelial cells increases glycoprotein Ibalphadependent adhesion to von Willebrand factor Beacham D.A.; Tran L.-P.; Shapiro S.S. Dr. D.A. Beacham, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107-5099 United States

Blood (BLOOD) (United States) 1997, 89/11 (4071-4077)

CODEN: BLOOA ISSN: 0006-4971 DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 41

9/3/8 (Item 1 from file: 155)

DIALOG(R) File 155: MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

10303207 20130051

Inhibition of corneal neovascularization by alpha(v)-integrin antagonists in the rat.

Klotz O; Park JK; Pleyer U; Hartmann C; Baatz H Franz Volhard Clinic at Max Delbruck Center for Molecular Medicine, Campus Buch, University Hospital Charite, Berlin, Germany.

Graefe's archive for clinical and experimental ophthalmology (GERMANY) Jan 2000, 238 (1) p88-93, ISSN 0721-832X Journal Code: FPR

Languages: ENGLISH

Document type: JOURNAL ARTICLE

9/3/9 (Item 2 from file: 155)

DIALOG(R) File 155: MEDLINE(R)

(c) format only 2000 Dialog Corporation. All rts. reserv.

10013874 99377072

Activation-dependent adhesion of human platelets Fisp12/mouse connective tissue growth factor is mediated through integrin alpha(IIb)beta(3).

Jedsadayanmata A; Chen CC; Kireeva ML; Lau LF; Lam SC

Department of Pharmacology, University of Illinois, Chicago, Illinois 60612, USA.

Journal of biological chemistry (UNITED STATES) p24321-7, ISSN 0021-9258 Journal Code: HIV Aug 20 1999,

Contract/Grant No.: HL41793, HL, NHLBI; CA46565, CA, NCI; CA80080, CA, NCI

Languages: ENGLISH

Document type: JOURNAL ARTICLE

? s s5 and review?

316 S5

2875350 REVIEW?

13 S5 AND REVIEW? S1·0

? t s10/7/all

(Item 1 from file: 73)

DIALOG(R) File 73: EMBASE

(c) 2001 Elsevier Science B.V. All rts. reserv.

07902875 EMBASE No: 1999376368

Angiogenesis and arthritis

D.A. Walsh, Rheumatology Acad. Univ. Nottingham, Clinical Sciences Building, City Hospital, Hucknall Road, Nottingham NG5 1PB United

Rheumatology (RHEUMATOL.) (United Kingdom) 1999, 38/2 (103-112)

CODEN: RUMAF ISSN: 1462-0324 DOCUMENT TYPE: Journal; Review

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 144

Indices of angiogenesis are increased in synovia from patients with arthritis, and vascular proliferation may contribute to the pathogenesis of synovitis, pannus growth, bone and cartilage destruction, and osteophyte formation. Pharmacological inhibition of angiogenesis therefore has potential as a therapeutic strategy in human arthritis. However, vascular growth is also essential for normal development, female reproduction and tissue repair. Selective inhibition of undesirable angiogenesis requires an understanding of the different regulatory mechanisms in pathological and physiological angiogenesis. This review outlines the evidence that the rate of angiogenesis is increased in the inflamed human synovium, and possible approaches to, and consequences of, the modulation of vascular growth.

10/7/2 (Item 1 from file: 155) DIALOG(R) File 155: MEDLINE(R) (c) format only 2000 Dialog Corporation. All rts. reserv. 08555052 96418252 REVIEW: the integrin alpha V beta 3: angiogenesis and apoptosis. Varner JA; Brooks PC; Cheresh DA Department of Immunology, Scripps Research Institute, La Jolla, CA 92037, Cell adhesion and communication (SWITZERLAND) Nov 1995, 3 (4) p367-74, ISSN 1061-5385 Journal Code: B4A Languages: ENGLISH Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL (60 Refs.) (Item 1 from file: 399) DIALOG(R) File 399:CA SEARCH(R) (c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv. CA: 134(13)176296a JOURNAL Integrin .alpha.v in health and disease - role of .alpha.v.beta.3 in metastasis, vascular remodeling and angiogenesis AUTHOR(S): Mousa, Shaker A.; Varner, Judith A.; Cheresh, David LOCATION: DuPont Pharmaceuticals Co., Wilmington, DE, USA JOURNAL: Med. Intell. Unit DATE: 2000 VOLUME: 20 NUMBER: Angiogenesis Inhibitors and Stimulators PAGES: 37-44 CODEN: MIUNFS ISSN: 1080-3645 LANGUAGE: English PUBLISHER: R. G. Landes Co. SECTION: CA214000 Mammalian Pathological Biochemistry IDENTIFIERS: review integrin alphav metastasis angiogenesis restenosis DESCRIPTORS: Integrins... .alpha.v.beta.3; integrin .alpha.v.beta.3 and .alpha.v.beta.5 roles in metastasis, vascular remodeling and angiogenesis Integrins... .alpha.v.beta.5; integrin .alpha.v.beta.3 and .alpha.v.beta.5 roles in metastasis, vascular remodeling and angiogenesis Angiogenesis... Apoptosis... integrin .alpha.v.beta.3 and .alpha.v.beta.5 roles in metastasis, vascular remodeling and angiogenesis Neoplasm... metastasis; integrin .alpha.v.beta.3 and .alpha.v.beta.5 roles in metastasis, vascular remodeling and angiogenesis Artery, disease... restenosis; integrin .alpha.v.beta.3 and .alpha.v.beta.5 roles in metastasis, vascular remodeling and angiogenesis

```
DIALOG(R) File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.
  133072048
               CA: 133(6)72048j
                                    JOURNAL
  Bone sialoprotein and the paradox of angiogenesis versus atherosclerosis
  AUTHOR(S): Dong, Chunming; Goldschmidt-Clermont, Pascal J.
· LOCATION: Heart and Lung Institute and Division of Cardiology, Department
of Internal Medicine, College of Medicine and Public Health, Ohio State
University, Columbus, OH, USA
  JOURNAL: Circ. Res. DATE: 2000 VOLUME: 86 NUMBER: 8 PAGES: 827-828
  CODEN: CIRUAL ISSN: 0009-7330 LANGUAGE: English PUBLISHER: Lippincott
Williams & Wilkins
  SECTION:
CA214000 Mammalian Pathological Biochemistry
CA202XXX Mammalian Hormones
  IDENTIFIERS: review bone sialoprotein angiogenesis atherosclerosis
  DESCRIPTORS:
Integrins...
    .alpha.v.beta.1; bone sialoprotein as an angiogenic factor in assocn.
    with initiation of atherosclerosis in human
Integrins...
    .alpha.v.beta.3; bone sialoprotein as an angiogenic factor in assocn.
    with initiation of atherosclerosis in human
    .alpha.v.beta.5; bone sialoprotein as an angiogenic factor in assocn.
    with initiation of atherosclerosis in human
Angiogenesis... Atherosclerosis... Calcification... Cell adhesion... Cell migration... Cell proliferation... Osteocalcins... Osteonectin...
Osteopontin... Sialoglycoproteins...
    bone sialoprotein as an angiogenic factor in assocn. with initiation of
    atherosclerosis in human
Sialoglycoproteins...
    BSP II (bone sialoglycoprotein II); bone sialoprotein as an angiogenic
    factor in assocn. with initiation of atherosclerosis in human
Blood vessel...
    endothelium; bone sialoprotein as an angiogenic factor in assocn. with
    initiation of atherosclerosis in human
Blood vessel...
    microvessel; bone sialoprotein as an angiogenic factor in assocn. with
    initiation of atherosclerosis in human
  CAS REGISTRY NUMBERS:
106096-93-9 127464-60-2 bone sialoprotein as an angiogenic factor in
    assocn. with initiation of atherosclerosis in human
            (Item 3 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.
               CA: 132(4)33950g
                                    JOURNAL
  Role of integrins in cancer: survey of expression patterns (44435)
  AUTHOR(S): Mizejewski, Gerald J.
  LOCATION: Molecular Medicine, Wadsworth Center, New York State Department
of Health, Albany, NY, 12201-0509, USA
  JOURNAL: Proc. Soc. Exp. Biol. Med. DATE: 1999 VOLUME: 222 NUMBER: 2
  PAGES: 124-138 CODEN: PSEBAA ISSN: 0037-9727 LANGUAGE: English
  PUBLISHER: Blackwell Science, Inc.
  SECTION:
CA214000 Mammalian Pathological Biochemistry
  IDENTIFIERS: review integrin cancer
  DESCRIPTORS:
Platelet(blood)...
    aggregation; integrins in cancer
Actinins...
```

(Item 2 from file: 399)

```
.alpha.-; integrins in cancer
Integrins...
    .alpha.v.beta.1; integrins in cancer
Integrins...
    .alpha.v.beta.3; integrins in cancer
Integrins...
    .alpha.v.beta.5; integrins in cancer
Integrins...
    .alpha.1.beta.1; integrins in cancer
Integrins...
    .alpha.2.beta.1; integrins in cancer
Integrins...
    .alpha.3.beta.1; integrins in cancer
Integrins...
    .alpha.4.beta.1; integrins in cancer
Integrins...
    .alpha.5.beta.1; integrins in cancer
Integrins...
    .alpha.6.beta.1; integrins in cancer
Diagnosis...
    cancer; integrins in cancer
Neoplasm...
    diagnosis; integrins in cancer
CD antigens... Integrins...
    integrin .alpha.7; integrins in cancer
Angiogenesis... Antitumor agents... Cell adhesion... Cell migration...
Cytoskeleton... Extracellular matrix... Integrins... Neoplasm... Prognosis
... Talin... Tumor markers... Vinculin...
    integrins in cancer
Signal transduction, biological...
    intercellular communication; integrins in cancer
Neoplasm...
    metastasis; integrins in cancer
Mammary gland...
    neoplasm; integrins in cancer
Cell aggregation...
    platelet; integrins in cancer
 10/7/6
             (Item 4 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.
               CA: 131(22)294990h
  131294990
                                       JOURNAL
  Anti-integrins as a potential therapeutic target in angiogenesis
  AUTHOR(S): Mousa, Shaker A.
  LOCATION: DuPont Pharmaceuticals, Co., Wilmington, DE, 19880, USA
  JOURNAL: Expert Opin. Ther. Pat. DATE: 1999 VOLUME: 9 NUMBER: 9 PAGES: 1237-1248 CODEN: EOTPEG ISSN: 1354-3776 LANGUAGE: English
  PUBLISHER: Ashley Publications
  SECTION:
CA201000 Pharmacology
  IDENTIFIERS: review integrin angiogenesis inhibitor design, ECM protein
integrin angiogenesis inhibitor review
  DESCRIPTORS:
Integrins...
    .alpha.v.beta.3; anti-integrins as a potential therapeutic target in
    angiogenesis
Integrins...
    .alpha.v.beta.5; anti-integrins as a potential therapeutic target in
    angiogenesis
Integrins...
    .alpha.5.beta.1; anti-integrins as a potential therapeutic target in
    angiogenesis
Angiogenesis inhibitors... Drug design...
```

anti-integrins as a potential therapeutic target in angiogenesis Proteins, specific or class... extracellular matrix-assocd.; anti-integrins as a potential therapeutic target in angiogenesis (Item 5 from file: 399) DIALOG(R) File 399:CA SEARCH(R) (c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv. CA: 131(11)142646n 131142646 JOURNAL . Fibronectin and its integrin receptors in cancer AUTHOR(S): Ruoslahti, Erkki LOCATION: Cancer Research Center, The Burnham Institute, La Jolla, CA, 92037, USA JOURNAL: Adv. Cancer Res. DATE: 1999 VOLUME: 76, PAGES: 1-20 CODEN: ACRSAJ ISSN: 0065-230X LANGUAGE: English PUBLISHER: Academic Press SECTION: CA214000 Mammalian Pathological Biochemistry IDENTIFIERS: review fibronectin integrin neoplasm metastasis DESCRIPTORS: Integrins... .alpha.IIb.beta.3; fibronectin and integrin receptors roles at several stages of tumor development and metastasis .alpha.v.beta.3; fibronectin and integrin receptors roles at several stages of tumor development and metastasis Integrins... .alpha.v.beta.6; fibronectin and integrin receptors roles at several stages of tumor development and metastasis .alpha.1.beta.1; fibronectin and integrin receptors roles at several stages of tumor development and metastasis Integrins... .alpha.5.beta.1; fibronectin and integrin receptors roles at several stages of tumor development and metastasis .alpha.6.beta.4; fibronectin and integrin receptors roles at several stages of tumor development and metastasis Angiogenesis... Cell adhesion... Cell migration... Fibronectins... Integrins... Neoplasm... fibronectin and integrin receptors roles at several stages of tumor development and metastasis Neoplasm... metastasis; fibronectin and integrin receptors roles at several stages of tumor development and metastasis Phosphoproteins... p125FAK; fibronectin and integrin receptors roles at several stages of tumor development and metastasis Phosphoproteins... SHC; fibronectin and integrin receptors roles at several stages of tumor development and metastasis CAS REGISTRY NUMBERS: 144114-16-9 fibronectin and integrin receptors roles at several stages of tumor development and metastasis (Item 6 from file: 399) 10/7/8 DIALOG(R) File 399:CA SEARCH(R) (c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv. 131030681 CA: 131(3)30681p **JOURNAL** The role of .alpha.v integrins during angiogenesis AUTHOR(S): Eliceiri, Brian P.; Cheresh, David A.

LOCATION: Departments of Immunology and Vascular Biology, The Scripps

35

100

```
Research Institute, La Jolla, CA, 92037, USA
JOURNAL: Mol. Med. (N. Y.) DATE: 1998 VOLUME: 4 NUMBER: 12 PAGES: 741-750 CODEN: MOMEF3 ISSN: 1076-1551 LANGUAGE: English PUBLISHER:
Springer-Verlag New York Inc.
  SECTION:
CA215000 Immunochemistry
CA213XXX Mammalian Biochemistry
CA214XXX Mammalian Pathological Biochemistry
  IDENTIFIERS: alphav integrin angiogenesis review
  DESCRIPTORS:
Integrins...
     .alpha.v.beta.3; .alpha.v integrins role during angiogenesis
    .alpha.v integrins role during angiogenesis
Integrins...
    .alpha.v; .alpha.v integrins role during angiogenesis
             (Item 7 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.
                CA: 130(18)235438r
                                         CONFERENCE PROCEEDING
  Integrin .alpha.v in health and disease-role of .alpha.v.beta.3 in
metastasis, vascular remodeling and angiogenesis
  AUTHOR(S): Varner, Judith A.
  LOCATION: Department of Medicine/Cancer Center, Cellular and Molecular
Medicine, University of California, La Jolla, CA, USA
  JOURNAL: Cell Adhes. Mol. Matrix Proteins EDITOR: Mousa, Shaker A (Ed),
  DATE: 1998 PAGES: 71-84 CODEN: 67CWAV LANGUAGE: English PUBLISHER:
Springer, Berlin, Germany
  SECTION:
CA214000 Mammalian Pathological Biochemistry
  IDENTIFIERS: review alphav integrin metastasis vascular remodeling .
angiogenesis
  DESCRIPTORS:
Integrin .alpha.v... Integrins...
    .alpha.v.beta.5; role of integrin .alpha.v.beta.3 in metastasis,
    vascular remodeling, and angiogenesis
Blood vessel...
    remodeling; role of integrin .alpha.v.beta.3 in metastasis, vascular
remodeling, and angiogenesis
Angiogenesis... Apoptosis... Arterial restenosis... Coronary artery
restenosis... Integrin .alpha.v.beta.3... Melanoma... Metastasis(tumor)...
    role of integrin .alpha.v.beta.3 in metastasis, vascular remodeling,
    and angiogenesis
              (Item 8 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.
                CA: 128(21)255388m CONFERENCE PROCEEDING
  The role of integrin .alpha.v.beta.3 in cell survival and angiogenesis AUTHOR(S): Stromblad, Staffan; Brooks, Peter C.; Becker, Jurgen;
Rosenfeld, Mauricio; Cheresh, David A.
  LOCATION: Departments of Immunology and Vascular Biology, Scripps
Research Institute, La Jolla, CA, 92037, USA
  JOURNAL: Program. Cell Death, (Proc. Int. Symp.) EDITOR: Shi, Yun-bod), DATE: 1997 PAGES: 35-42 CODEN: 65SWAT LANGUAGE: English
  MEETING DATE: 19960000 PUBLISHER: Plenum, New York, N. Y
  SECTION:
CA213000 Mammalian Biochemistry
  IDENTIFIERS: review integrin cell survival angiogenesis
```

DESCRIPTORS:

```
Angiogenesis... Apoptosis... Integrin .alpha.v.beta.3...
    role of integrin .alpha.v.beta.3 in cell survival and angiogenesis
             (Item 9 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.
               CA: 128(6)60426q
                                   JOURNAL
  128060426
  Integrin .alpha.v.beta.3: a therapeutic target
 AUTHOR(S): Brooks, Peter C.
  LOCATION: Dept. of Biochemistry, Norris Cancer Center, University of
Southern California, Los Angeles, CA, 90033, USA
  JOURNAL: Drug News Perspect. DATE: 1997 VOLUME: 10 NUMBER: 8 PAGES:
456-461 CODEN: DNPEED ISSN: 0214-0934 LANGUAGE: English PUBLISHER: J.
R. Prous, S.A.
  SECTION:
CA215000 Immunochemistry
  IDENTIFIERS: review integrin alphaVbeta3 tumor angiogenesis
  DESCRIPTORS:
Angiogenesis... Integrin .alpha.v.beta.3... Tumors(animal)...
    integrin .alpha.v.beta.3 in tumor progression and angiogenesis is a
    therapeutic target
 10/7/12
             (Item 10 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.
              CA: 127(17)229023y
                                     JOURNAL
  Stereoisomeric peptide libraries and peptidomimetics for designing
selective inhibitors of the .alpha.v.beta.3 integrin for a new cancer
  AUTHOR(S): Haubner, Roland; Finsinger, Dirk; Kessler, Horst
  LOCATION: Nuklearmedizinische Klinik Polyklinik, Technischen Universitat 😥
Munchen, Germany,
  JOURNAL: Angew. Chem., Int. Ed. Engl. DATE: 1997 VOLUME: 36 NUMBER:
13/14 PAGES: 1374-1389 CODEN: ACIEAY ISSN: 0570-0833 LANGUAGE: English
  PUBLISHER: Wiley-VCH
  SECTION:
CA201000 Pharmacology
  IDENTIFIERS: review antitumor integrin inhibitor peptide library
  DESCRIPTORS:
Integrin .alpha.v.beta.3...
    antagonists; stereoisomeric peptide libraries and peptidomimetics for
    designing selective inhibitors of the .alpha.v.beta.3 integrin for a
    new cancer therapy
Angiogenesis inhibitors... Drug design...
    stereoisomeric peptide libraries and peptidomimetics for designing
    selective inhibitors of the .alpha.v.beta.3 integrin for a new cancer
    therapy
Peptide library...
   · stereoisomeric; stereoisomeric peptide libraries and peptidomimetics
    for designing selective inhibitors of the .alpha.v.beta.3 integrin for
    a new cancer therapy
             (Item 11 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.
  124284943
              CA: 124(21)284943m
                                     JOURNAL
  The integrin .alpha.v.beta.3: angiogenesis and apoptosis
```

AUTHOR(S): Varner, Judith A.; Brooks, Peter C.; Cheresh, David A.

LOCATION: Department of Immunology, Scripps Research Institute, La Jolla,

CA, 92037, USA JOURNAL: Cell Adhes. Commun. DATE: 1995 VOLUME: 3 NUMBER: 4 PAGES: 367-74 CODEN: CADCEF ISSN: 1061-5385 LANGUAGE: English SECTION: CA213000 Mammalian Biochemistry IDENTIFIERS: review integrin angiogenesis apoptosis DESCRIPTORS: Blood vessel...

formation; integrin .alpha.v.beta.3 in angiogenesis and apoptosis Apoptosis... Integrins, .alpha.v.beta.3... integrin .alpha.v.beta.3 in angiogenesis and apoptosis

(Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

12850011 BIOSIS NO.: 200100057160

Abciximab inhibits the migration and invasion potential of human coronary artery smooth muscle cells.

AUTHOR: Blindt Ruediger(a); Bosserhoff Anja-Katrin; Zeiffer Ute; Krott Nicole; Hanrath Peter; vom Dahl Juergen

AUTHOR ADDRESS: (a) Medical Clinic I, University Hospital, RWTH Aachen, Pauwelsstr 30, 52074, Aachen: ruediger.blindt@post.rwth-aachen.de**

JOURNAL: Journal of Molecular and Cellular Cardiology 32 (12):p2195-2206

December, 2000 MEDIUM: print ISSN: 0022-2828

DOCUMENT TYPE: Article RECORD TYPE: Abstract LANGUAGE: English

SUMMARY LANGUAGE: English

ABSTRACT: In the EPIC trial, high-risk patients received the integrin receptor antagonist abciximab v placebo during and for 12 h following percutaneous coronary intervention with a significant 23% decrease of repeat revascularisation at 6 months. However, EPILOG and CAPTURE trials could not confirm these promising long-term results. Recently presented data from the EPISTENT trial suggested a beneficial effect of abciximab; on restenosis in patients with diabetes. Based on these divergent results the aim of this study was to test whether alphavbeta3 receptor blockade by abciximab could cause inhibition of human coronary smooth muscle cell (hcSMC) proliferation, migration, and invasion which represent crucial steps during restenosis development. In contrast to quiescent hcSMCs, proliferating cells were capable to migrate towards chemoattractive stimuli and even capable to invade through a basement membrane equivalent. Abciximab and LM609, an alphavbeta3 specific inhibiting antibody, caused only a modest dose-dependent inhibition of hcSMC proliferation. On the contrary, the chemotactic and invasive potential of hcSMCs was significantly inhibited by abciximab administration 24 h prior to and during migration. (IC50 = 33.0 mug/ml for chemotaxis and IC50 = 0.5 mug/ml for invasion). For LM609 similar results were obtained. Administration of the drugs just during migration without pretreatment inhibited migration equally but invasion to a lower extent (abciximab: IC50 = 32.6 mug/ml for chemotaxis and IC50 = 44.9 mug/ml for invasion; LM609 IC50 = 3.1mug/ml for chemotaxis and IC50 = 2.0 mug/ml for invasion). The attachment to the extracellular matrix proteins collagen I, collagen IV, laminin and vitronectin was not influenced. Pretreatment for 24 h with abciximab or LM609 did not cause a downregulation of the alphavbeta3-integrin receptor. The results of this study indicate that the alphavbeta3 antagonist abciximab is a potent inhibitor of hcSMC migration and invasion which could explain the observed lower reintervention rate after PTCA and stent implantation.

(Item 2 from file: 5) DIALOG(R) File 5: Biosis Previews(R) (c) 2001 BIOSIS. All rts. reserv.

BIOSIS NO.: 200100035474

Inhibition of vascular smooth muscle cell adhesion and migration by c7E3

Fab (abciximab): A possible mechanism for influencing restenosis.

AUTHOR: Baron Julia H(a); Moiseeva Elena P; de Bono David P; Abrams Keith R ; Gershlick Anthony H

AUTHOR ADDRESS: (a) Division of Cardiology, Department of Medicine and Therapeutics, University of Leicester, Leicester**UK

JOURNAL: Cardiovascular Research 48 (3):p464-472 December, 2000

MEDIUM: print ISSN: 0008-6363

DOCUMENT TYPE: Article RECORD TYPE: Abstract

12828325 BIOSIS NO.: 200100035474

Inhibition of vascular smooth muscle cell adhesion and migration by c7E3 Fab (abciximab): A possible mechanism for influencing restenosis.

AUTHOR: Baron Julia H(a); Moiseeva Elena P; de Bono David P; Abrams Keith R; Gershlick Anthony H

AUTHOR ADDRESS: (a) Division of Cardiology, Department of Medicine and Therapeutics, University of Leicester, Leicester**UK

Therapeutics, university of Leicester, Leicester and

JOURNAL: Cardiovascular Research 48 (3):p464-472 December, 2000

MEDIUM: print ISSN: 0008-6363

DOCUMENT TYPE: Article RECORD TYPE: Abstract LANGUAGE: English

SUMMARY LANGUAGE: English

ABSTRACT: Objectives: Brief intravenous administration of chimeric antibody c7E3 Fab during coronary angioplasty has been shown in some studies to provide long term protection against coronary events. Smooth muscle cell (SMC) adhesion and migration are key initial steps in the development of restenosis. The purpose of this study was to investigate the effect of c7E3 Fab on adhesion and migration of SMC to the extracellular matrix (ECM) proteins osteopontin (Opn) and vitronectin (Vn). Methods: Adhesion of human vascular SMCs to ECM proteins was quantified using a CyQUANT assay kit. Migration of SMCs to Vh, Opn and PDGF was studied using a modified Boyden's chamber migration assay. Integrin expression was determined by immunoprecipitation. Results: c7E3 Fab reduced SMC adhesion on Vn and Opn to 69.2+-3.3% (P<0.001) and 52.5+-4.8% (P<0.001) respectively, compared to adhesion without antibody present. This reduction was the same as that for anti-alphavbeta3 integrin antibody LM609 (P=0.5). The combination of anti-alphavbeta5, integrin antibody and c7E3 Fab had a greater effect than either antibody alone (P<0.001). c7E3 Fab reduced SMC migration to Vn and Opn to 51.6+-8.9% (P<0.001) and 20.3+-6.1% (P<0.001) respectively, compared to migration in the absence of antibodies. Again, similar results were seen with LM609. PDGF-induced SMC migration was also inhibited by c7E3 Fab (P=0.004) and LM609 (P=0.001), but to much less an extent. The migration SMCs from a culture found not to express the alphavbeta3 integrin was unaffected by these antibodies, strengthening the argument that c7E3 Fab inhibits SMC function via this integrin. Conclusions: c7E3 Fab inhibits the adhesion and migration of SMCs via the alphavbeta3 integrin. The inhibition, however, is partial, and varied depending on type of ECM protein and alphavbeta3 integrin expression. Some of the clinical benefits of c7E3 Fab may be due to its effect on SMCs.

```
s (alphav(w)beta3 or alpha(w)v(w)beta(w)3) and angiogenesis
Processing
             990 ALPHAV
            6077
                  BETA3
             101 ALPHAV (W) BETA3
         1610335
                 ALPHA
          850417
         1578874 BETA
         6018160 3
            2783 ALPHA(W)V(W)BETA(W)3
           39310 ANGIOGENESIS
      S4
             385 (ALPHAV(W)BETA3 OR ALPHA(W)V(W)BETA(W)3) AND ANGIOGENESIS
? rd s4
...examined 50 records
                       (50)
...examined 50 records
                       (100)
...examined 50 records
                       (150)
...examined 50 records
                       (200)
...examined 50 records (250)
...examined 50 records (300)
...examined 50 records (350)
...completed examining records
      S5
            316 RD S4 (unique items)
? s s5 and py=1992
             316 S5
         1848808 PY=1992
      S6
               2 S5 AND PY=1992
? t s6/7/all
           (Item 1 from file: 5)
DIALOG(R) File
               5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.
          BIOSIS NO.: 000043039234
MODULATION OF MICROVASCULAR ENDOTHELIAL CELL VNR GROWTH FACTORS AND GAMMA
  INTERFERON
AUTHOR: SWERLICK R A; LAWLEY T J; LI L J; CAUGHMAN S W; LEE K H; SEPP N T
AUTHOR ADDRESS: EMORY UNIV., ATLANTA, GA. 30322.
JOURNAL: KEYSTONE SYMPOSIUM ON INTEGRINS: CELL ADHESION AND TRANSMEMBRANE
COMMUNICATION IN DEVELOPMENT AND DISEASE, KEYSTONE, COLORADO, USA, APRIL
3-10, 1992. J CELL BIOCHEM SUPPL 0 (16 PART F). 1992. 180. 1992
CODEN: JCBSD
DOCUMENT TYPE: Meeting
RECORD TYPE: Citation
LANGUAGE: ENGLISH
           (Item 1 from file: 155)
DIALOG(R) File 155: MEDLINE(R)
(c) format only 2000 Dialog Corporation. All rts. reserv.
07399406
          93046914
  Thrombospondin as a mediator of cancer cell adhesion in metastasis.
 Walz DA
 Wayne State University School of Medicine, Department of Physiology,
Detroit, MI 48201.
 Cancer and metastasis reviews (UNITED STATES) Nov 1992, 11 (3-4)
```

p313-24, ISSN 0891-9992 Journal Code: C9H Contract/Grant No.: HL 27073, HL, NHLBI

Languages: ENGLISH

Document type: JOURNAL ARTICLE; REVIEW; REVIEW, ACADEMIC

Thrombospondin (TSP) is a 450 kDa adhesive glycoprotein. It is present in high concentrations in the platelet alpha-granule and can readily be secreted following platelet activation where local concentrations can be increased by 3-4 orders of magnitude. TSP is also synthesized by a variety of other cells and is incorporated into their extracellular matrix. TSP is a homotrimer with a number of functional domains, at least four of which might serve as receptor recognizing regions. The amino-terminal heparin domain interacts with heparin, other glycosaminoglycans and binding glycolipids and likely recognizes specific cell surface proteoglycans. The central disulfide cross-linked region, 210 kDa non-reduced and 70 kDa reduced, contains a peptide motif CSVTCG which is apparently responsible for binding to glycoprotein IV (CD36) with high affinity. Immediately adjacent to the calcium binding region of TSP, which undergoes considerable molecular relaxation in the absence of calcium, is an RGDA sequence. TSP has been demonstrated to bind to integrins of the ${\tt alpha}\ {\tt v}$ beta 3 and alpha IIb beta 3 class. The carboxy-terminal region of TSP also contains at least one binding epitope for a cell receptor. There are 2 well characterized genes for TSP and truncated forms of TSP have been detected which have inhibitory effects on angiogenesis. Finally, TSP can interact with fibrinogen and fibronectin, perhaps on cellular surfaces, which might serve as secondary receptor-like mechanisms for TSP binding and subsequent mediation of cell adhesion. (131 Refs.) ? s s5 and py=1993

316 S5 1856109 PY=1993 S7 3 S5 AND PY=1993 ? t s7/7/all

7/7/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

(c) 2001 BIOSIS. All rts. reserv.
09020568 BIOSIS NO.: 199497028938
Basic fibroblast growth factor modulates integrin expression in

microvascular endothelial cells.

AUTHOR: Klein Sharon(a); Giancotti Filippo G; Presta Marco; Albelda Steven M; Buck Clayton A; Rifkin Daniel B

AUTHOR ADDRESS: (a) Dep. Cell Biol., New York Univ. Med. Cent., New York, NY 10016**USA

JOURNAL: Molecular Biology of the Cell 4 (10):p973-982 1993

ISSN: 1059-1524

DOCUMENT TYPE: Article RECORD TYPE: Abstract LANGUAGE: English

ABSTRACT: During angiogenesis capillary endothelial cells undergo a coordinated set of modifications in their interactions with extracellular matrix components. In this study we have investigated the effect of the prototypical angiogenic factor basic fibroblast growth factor (bFGF) on the expression and function of several integrins in microvascular endothelial cells. Immunoprecipitation experiments with antibodies to individual subunits indicated that microvascular cells express at their surface several integrins. These include the alpha-1-beta-1, alpha-2-beta-1, and alpha-3-beta-1 laminin/collagen receptors; the alpha-6-beta-1 laminin receptor; the alpha-5-beta-1 and alpha-v-beta-1 fibronectin receptors; the alpha-6-beta-4 basement membrane receptor; and the alpha-v-beta-3 and alpha-v-beta-5 vitronectin receptors. Treatment with bFGF caused a significant increase in the surface expression of the alpha-2-beta-1, alpha-3-beta-1, alpha-5-beta-1, alpha-6-beta-1, alpha-6-beta-4, and alpha-v-beta-5 integrins. In

contrast, the level of expression of the alpha-1-beta-1 and alphav-beta-3 integrins was decreased in bFGF-treated cells. Immunoprecipitation of metabolically labeled cells indicated that bFGF increases the biosynthesis of the alpha-3, alpha-5, alpha-6, beta-4, and beta-5 subunits and decreases the production of the alpha-v and beta-3 subunits. These results suggest that bFGF modulates integrin expression by altering the biosynthesis of individual alpha or beta subunits. In accordance with the upregulation of several integrins observed in bFGF-treated cells, these cells adhered better to fibronectin, laminin, vitronectin, and type I collagen than did untreated cells. The largest differences in beta-1. integrin expression occurred apprx 72 h after exposure to bFGF, at a time when the expression of the endothelial cell-to-cell adhesion molecule endoCAM was also significantly upregulated. In contrast, a shorter exposure to bFGF (24-48 h) was required for the maximal induction of plasminogen activator production in the same cells. Taken together, these results show that bFGF causes significant changes in the level of expression and function of several integrins in microvascular endothelial cells.

7/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

08982517 BIOSIS NO.: 199396134018 Endothelial cells adhere to the RGD domain and the fibrinogen-like terminal knob of tenascin.

AUTHOR: Joshi Paritosh; Chung Chang-Y; Aukhil Ikramuddin; Erickson Harold P

AUTHOR ADDRESS: (a) Dep. Cell Biol., Duke Univ. Med. Cent., Durham, NC 27710

JOURNAL: Journal of Cell Science 106 (1):p389-400 1993

ISSN: 0021-9533

DOCUMENT TYPE: Article RECORD TYPE: Abstract LANGUAGE: English

ABSTRACT: We have found that endothelial cells adhere much more strongly than fibroblasts to domains of tenascin and fibronectin. Endothelial cells adhered weakly, without spreading, to bacterial expression proteins corresponding to the tenth fibronectin type III (FN-III) domain of fibronectin, which contains the RGD. A larger fibronectin protein, containing this domain and the three amino-terminal 'synergy' domains gave strong adhesion and spreading. Two widely separated domains of tenascin gave adhesion. The third FN-III domain, TNfn3, which contains an RGD sequence in human and chicken tenascin, gave very strong adhesion and spreading of endothelial cells when tested as an isolated domain. Larger segments containing TNfn3 and the adjacent TNfn2 gave weaker adhesion, probably because the RGD sequence is partially blocked. Adhesion to this domain required divalent cations, was exquisitely sensitive to soluble GRGDSP peptide, and was blocked by antisera to the integrin alphav-beta-3. The second tenascin adhesion domain was the fibrinogen-like C-terminal knob, TNfbg. Cells adhered to but did not spread on this domain. This adhesion required divalent cations and was also sensitive to GRGDSP peptide, so it may be mediated by an integrin receptor. We have explored a range of conditions for preparing the adhesion substratum, and our results may resolve the controversy over whether tenascin can act as a substratum adhesion molecule. When coated for short times (1-2 hours) on plastic, tenascin had no adhesion activity, in contrast to fibronectin and the expression proteins, which gave strong adhesion under these conditions. When coated for longer times (12-24 hours) on plastic, the tenascin substratum supported good adhesion, but not spreading, of endothelial cells. Tenascin coated on nitrocellulose gave substantially stronger adhesion than on plastic, but still required long coating times for maximal activity. Adhesion of endothelial cells to native TN was inhibited by GRDGSP peptide. The cell

adhesion activity demonstrates the presence on endothelial cells of tenascin receptors, which may play a supportive role in angiogenesis, in the structure of blood vessels, or in binding tenascin to the cell surface to elicit or enhance a signalling function.

7/7/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

08827884 BIOSIS NO.: 199395117235

Identification of a role of the vitronectin receptor and protein kinase C in the induction of endothelial cell vascular formation.

AUTHOR: Davis Cynthia M(a); Danehower Susan C; Laurenza Antonio; Molony J Leslie

AUTHOR ADDRESS: (a) Cell Biol. Dep., R and D 3.3244, Glaxo Inc. Res. Inst.,

5 Moore Drive, Research Triangle Park, N**USA

JOURNAL: Journal of Cellular Biochemistry 51 (2):p206-218 1993

ISSN: 0730-2312

DOCUMENT TYPE: Article RECORD TYPE: Abstract LANGUAGE: English

ABSTRACT: When cultured on a basement membrane substratum, endothelial cells undergo a rapid series of morphological and functional changes which result in the formation of histotypic tube-like structures, a process which mimics in vivo angiogenesis. Since this process is probably dependent on several cell adhesion and cell signaling phenomena, we examined the roles of integrins and protein kinase C in endothelial cell cord formation. Polyclonal antisera directed against the entire vitronectin (alpha-v-beta-3) and fibronectin (alpha-5-beta-1) receptors inhibited cord formation. Subunit-specific monoclonal antibodies to alpha-v, beta-3, and beta-1 integrin subunits inhibited cord formation, while monoclonal antibodies to alpha-5 did not, which implicated the vitronectin receptor, and not the fibronectin receptor, in vascular formation. Protein kinase C inhibitors inhibited cord formation, while phorbol 12-myristate 13-acetate (PMA) caused endothelial cells to form longer cords. Since the vitronectin receptor has been shown to be phosphorylated in an in vitro system by protein kinase C, the possible functional link between the vitronectin receptor and protein kinase C during cellular morphogenesis was examined. The vitronectin receptor was more highly phosphorylated in cord-forming endothelial cells on basement membrane than in monolayer cells on vitronectin. Furthermore, this phosphorylation was inhibited by protein kinase C inhibitors, and PMA was required to induce vitronectin receptor phosphorylation in endothelial cells cultured on vitronectin. Colocalization studies were also performed using antisera to the vitronectin receptor and antibodies to protein kinase C. Although no strict colocalization was found, protein kinase C was localized in the cytoskeleton of endothelial cells initially plated on basement membrane or on vitronectin, and it translocated to the plasma membrane of C-shaped cord-forming cells on basement membrane. Thus, both the vitronectin receptor and protein kinase C play a role in in vitro cord formation. ? s s5 and py=1994

316 S5 1909655 PY=1994 S8 5 S5 AND PY=1994 ? t s8/7/all

8/7/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

09640154 BIOSIS NO.: 199598095072

Integrin alpha-v-beta-3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. AUTHOR: Brooks Peter C(a); Montgomery Anthony M P(a); Rosenfeld Mauricio(a) ; Reisfeld Ralph A(a); Hu Tianhua; Klier George; Cheresh David A(a) AUTHOR ADDRESS: (a) Dep. Immunol., Scripps Research Inst., La Jolla, CA 92037**USA JOURNAL: Cell 79 (7):p1157-1164 1994 ISSN: 0092-8674 DOCUMENT TYPE: Article RECORD TYPE: Abstract LANGUAGE: English ABSTRACT: A single intravascular injection of a cyclic peptide or monoclonal antibody antagonist of integrin alpha-v-beta -3 disrupts ongoing angiogenesis on the chick chorioallantoic membrane (CAM). This leads to the rapid regression of histologically distinct human tumors transplanted onto the CAM. Induction of angiogenesis by a tumor or cytokine promotes vascular cell entry into the cell apoptosis of the proliferative angiogenic vascular cells, leaving preexisting quiescent blood vessels unaffected. We demonstrate therefore that ligation of integrin alpha-v-beta-3 is required for the survival and maturation of newly forming blood vessels, an event essential for the proliferation of tumors. (Item 2 from file: 5) 8/7/2 DIALOG(R) File 5: Biosis Previews(R) (c) 2001 BIOSIS. All rts. reserv. BIOSIS NO.: 199598066052 Integrin alpha-v-beta-3 differentially regulates adhesive and phagocytic functions of the fibronectin receptor alpha-4-beta-1. AUTHOR: Blystone S D; Graham I L; Lindberg F P; Brown E J AUTHOR ADDRESS: Dep. Med., Infect. Dis. Div., Washington Univ. Sch. Med., St. Louis, MO 63110**USA JOURNAL: Molecular Biology of the Cell 5 (SUPPL.):p182A 1994 CONFERENCE/MEETING: Thirty-fourth Annual Meeting of the American Society for Cell Biology San Francisco, California, USA December 10-14, 1994 ISSN: 1059-1524 RECORD TYPE: Citation LANGUAGE: English (Item 3 from file: 5) 8/7/3 5:Biosis Previews(R) DIALOG(R) File (c) 2001 BIOSIS. All rts. reserv. BIOSIS NO.: 199598051572 09596654 Integrin alpha-v-beta-3 differentially regulates adhesive and phagocytic functions of the fibronectin receptor alpha-5-beta-1. AUTHOR: Blystone Scott D; Graham Irene L; Lindberg Frederik P; Brown Eric J AUTHOR ADDRESS: (a) Infectious Diseases, Campus Box 8051, Washington University Sch. Med., St. Louis, MO 63110**USA JOURNAL: Journal of Cell Biology 127 (4):p1129-1137 1994 ISSN: 0021-9525 DOCUMENT TYPE: Article RECORD TYPE: Abstract LANGUAGE: English

ABSTRACT: The plasma protein fibronectin is an important opsonin in wound repair and host defense. To better understand the process of fibronectin-mediated phagocytosis, we have transfected K562 cells, which endogenously express alpha-5-beta-1, with alpha-v-beta-

3. In these transfectants, antibodies to alpha-v-beta-3 block phagocytosis of fibronectin-opsonized beads completely, even though half the ingestion occurs through endogenous alpha-5-beta-1 receptors. alpha-5-beta-1-mediated adhesion to fibronectin-coated surfaces is unaffected by alpha-v-beta-3 ligation. Neither alpha-v-beta-5 nor alpha-M-beta-2 ligation affects alpha-5-beta-1 phagocytic function in transfectants expressing these receptors. Pharmacologic data suggest that alpha-v-beta-3 ligation suppresses the phagocytic competence of high affinity alpha-5-beta-1 receptors through a signal transduction pathway, perhaps involving protein kinase C. In addition to its significance for phagocytosis, alpha-v-beta-3 regulation of alpha-5-beta-1 function may be significant for its roles in cell migration, metastasis, and angiogenesis.

8/7/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

09483883 BIOSIS NO.: 199497492253
Basic fibroblast growth factor increases expression of the alphav-beta-3 integrin complex on human microvascular endothelial cells.

AUTHOR: Sepp Norbert T; Li Lian-Jie; Lee Kwang H; Brown Eric J; Caughman S Wright; Lawley Thomas J; Swerlick Robert A(a)
AUTHOR ADDRESS: (a) Dep. Dermatol., WMB 5014, Emory Univ., Atlanta, GA 30322

JOURNAL: Journal of Investigative Dermatology 103 (3):p295-299 1994

ISSN: 0022-202X

DOCUMENT TYPE: Article RECORD TYPE: Abstract LANGUAGE: English

ABSTRACT: Modulation of the expression of the alpha-vbeta-3 complex on human dermal microvascular endothelial cells (HDMEC) may be crucial in wound healing and angiogenesis. Therefore, we examined the influence of basic fibroblast growth factor (bFGF), transforming growth factor beta, and interferon-gamma (IFN-gamma) on the expression of this complex. Stimulation of HDMEC with bFGF increased cell surface expression of both alpha-v and beta-3 in a doseand time-dependent manner associated with the development of a spindled, elongated cell morphology. Northern blot analysis of HDMEC stimulated with bFGF demonstrated a marked increase in beta-3 but not alpha-v mRNA expression. Incubation of HDMEC with transforming growth factor-beta or interferon-y alone resulted in modest decreases in cell surface alpha-v,beta-3, and co-incubation of HDMEC with bFGF and transforming growth factor-beta or interferon-gamma inhibited bFGF-induced changes in cell morphology, increases in cell surface alpha-v-beta-3 expression, and increases in beta-3 mRNA. These data demonstrate that both growth factors and proinflammatory cytokines alter the expression of alpha-vbeta-3, on microvascular endothelial cells and that these alterations correlate with changes in cell morphology.

8/7/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

09257747 BIOSIS NO.: 199497266117

Requirement of vascular integrin alpha-v-beta-3 for angiogenesis.

AUTHOR: Brooks Peter C; Clark Richard A F; Cheresh David A(a)
AUTHOR ADDRESS: (a) Dep. Immunol., Scripps Res. Inst., 10666 North Torrey
Pines Road, La Jolla, CA 92037**USA

JOURNAL: Science (Washington D C) 264 (5158):p569-571 1994

ISSN: 0036-8075

DOCUMENT TYPE: Article RECORD TYPE: Abstract LANGUAGE: English

ABSTRACT: Angiogenesis depends on the adhesive interactions of vascular cells. The adhesion receptor integrin alpha-v-beta-3 was identified as a marker of angiogenic vascular tissue. Integrin alpha-v-beta-3 was expressed on blood vessels in human wound granulation tissue but not in normal skin, and it showed a fourfold increase in expression during angiogenesis on the chick chorioallantoic membrane. In the latter assay, a monoclonal antibody to alpha-v-beta-3 blocked angiogenesis induced by basic fibroblast growth factor, tumor necrosis factor-alpha, and human melanoma fragments but had no effect on preexisting vessels. These findings suggest that alpha-v-beta-3 may be a useful therapeutic target for diseases characterized by neovascularization.

Generate Collection

L1: Entry 25 of 33

File: USPT

Jul 29, 1997

US-PAT-NO: 5652109

DOCUMENT-IDENTIFIER: US 5652109 A

TITLE: Antibodies to .alpha.v.beta.3 integrin DATE-ISSUED: July 29, 1997

US-CL-CURRENT: $\underline{435}/\underline{7.1}$; $\underline{424}/\underline{141.1}$, $\underline{424}/\underline{143.1}$, $\underline{435}/\underline{332}$, $\underline{435}/\underline{334}$, $\underline{530}/\underline{388.1}$

APPL-NO: 8/ 432542

DATE FILED: May 2, 1995

PARENT-CASE:

CROSS REFERENCES This application is a continuation of U.S. application Ser. No. 08/307,844 filed 30 Sep. 1994, which application is a 371 of PCT/US93/02987 filed Mar. 30, 1993, now U.S. Pat. No. 5,578,704 which application is a continuation in part of U.S. application Ser. No. 08/025,913 filed 3 Mar. 1993 (abandoned), which application is a continuation of U.S. application Ser. No. 07/862,679 filed 3 Apr. 1992 (abandoned), which applications are incorporated herein by reference and to which applications priority is claimed under 35 USC .sctn 120.

3/7/55 (Item 19 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2001 Elsevier Science B.V. All rts. reserv.

04881743 EMBASE No: 1992021958

Recognition of osteopontin and related peptides by an alpha(v) betainf 3 integrin stimulates immediate cell signals in osteoclasts

Miyauchi A.; Alvarez J.; Greenfield E.M.; Teti A.; Grano M.; Colucci S.; Zambonin-Zallone A.; Ross F.P.; Teitelbaum S.L.; Cheresh D.; Hruska K.A. Department of Medicine, Jewish Hosp Wash. Univ Med Ctr, St. Louis, MO

63110 United States

Journal of Biological Chemistry (J. BIOL. CHEM.) (United States) 1991 266/30 (20369-20374)

CODEN: JBCHA ISSN: 0021-9258 DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

We have investigated the nature of immediate cell signals produced by occupancy of the chicken osteoclast alpha(v)betainf 3 integrin. Synthetic osteopontin and peptides from the osteopontin and bone sialoprotein sequences containing Arg-Gly-Asp stimulated immediate reductions in osteoclast cytosolic Casup 2sup +. The changes in cytosolic Casup 2sup + required the Arg-Gly-Asp sequence and were blocked by a monoclonal antibody to the alpha(v)betainf 3 integrin, IM609. Osteoclast stimulation by the proteins through the integrin did not require immobilization since soluble peptides produced changes in cytosolic Casup 2sup + and inhibited osteoclast binding to bone particles and bone resorption. The decrease in cytosolic Casup 2sup + stimulated by osteopontin and related peptides appeared to be due to activation of a plasma membrane Casup 2sup +-ATPase by calmodulin. Thus, the data suggest that ligand binding to the osteoclast alpha(v)betainf 3 integrin results in calmodulin-dependent reduction in cytosolic Casup 2sup + which participates

07430756 BIOSIS NO.: 000091036745

THE VITRONECTIN RECEPTOR ALPHA-V-BETA-3 BINDS FIBRONECTIN AND ACTS IN CONCERT WITH ALPHA-5-BETA-1 IN PROMOTING CELLULAR ATTACHMENT AND SPREADING ON FIBRONECTIN

AUTHOR: CHARO I F; NANNIZZI L; SMITH J W; CHERESH D A AUTHOR ADDRESS: COR THERAPEUTICS, INC., SOUTH SAN FRANCISCO, CALIF 94080. JOURNAL: J CELL BIOL 111 (6 PART 1). 1990. 2795-2800. 1990

FULL JOURNAL NAME: Journal of Cell Biology

CODEN: JCLBA

RECORD TYPE: Abstract LANGUAGE: ENGLISH

ABSTRACT: The vitronectin receptor (.alpha.v.beta.3) is a member of the integrin superfamily of adhesive protein receptors that mediate a wide spectrum of adhesive cellular interactions, including attachment to vitronectin, von Willebrand factor, fibrinogen, and thrombospondin. We have studied the binding of fibronectin to the purified vitronectin receptor, and the role of this receptor in the attachment of cells to fibronectin. A solid-phase microtiter assay was developed to investigate the binding properties of the vitronectin receptor. Purified .alpha.v.beta.3 bound fibronectin with high affinity in a saturable, divalent cation-dependent manner. Binding was inhibited by soluble vitronectin, by RGD-containing peptides, and by LM609, a monoclonal antibody against the vitronectin receptor known to inhibit the binding of adhesive proteins to .alpha.v.beta.3. Immunoinhibition experiments showed that M21 humanmelanoma cells, which express the fibronectin receptor, .alpha.5.beta.1, as well as .alpha.v.beta.3, used both of these integrins to attach and spread on fibronectin. In support of this finding, M21-L cells, a varient cell line that specifically lacks .alpha.v.beta.3 but expresses .alpha.v.beta.1, attached and spread poorly on fibronectin. In addition, .alpha.v.beta.3 from surface-labeled M21 cells was retained, and selectively eluted by RGDS from a fibronectin affinity column. These rsults indicate that .alpha.v.beta.3 acts in concert with .alpha.5.beta.1 in promoting fibronectin recognition by these cells. We conclude that fibronectin binds to the .alpha.v.beta.3 vitronectin receptor specifically and with high affinity, and that this interaction is biologically relevant in supporting cell adhesion to

3/7/36 (Item 36 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

05767873 BIOSIS NO.: 000084116280 HUMAN ENDOTHELIAL CELLS SYNTHESIZE AND EXPRESS AN ARG-GLY-ASP-DIRECTED ADHESION RECEPTOR INVOLVED IN ATTACHMENT TO FIBRINOGEN AND VON WILLEBRAND FACTOR

AUTHOR: CHERESH D A

AUTHOR ADDRESS: DEP. IMMUNOL., SCRIPPS CLINIC RES. FOUND., 10666 NORTH

TORREY PINES ROAD, LA JOLLA, CALIF. 92037.

JOURNAL: PROC NATL ACAD SCI U S A 84 (18). 1987. 6471-6475. 1987

FULL JOURNAL NAME: Proceedings of the National Academy of Sciences of the

United States of America

CODEN: PNASA

RECORD TYPE: Abstract LANGUAGE: ENGLISH

ABSTRACT: Human umbilical vein endothelial cells express a heterodimeric adhesion receptor complex consisting of noncovalently associated .alpha. and .beta. subunits that under reducing conditions have molecular masses of 135 kDa and 115 kDa, respectively. This complex can be isolated in pure form from an affinity matrix consisting of an Arg-Asp-containing hepatapeptide and is specifically immunoprecipitated with monoclonal antibodies (mAbs) directed against the vitronectin receptor of human . melanoma cells. These data suggest that this complex is one member of a large family of cell adhesion receptors. One of the mAbs, LM609, inhibits the attachment of human endothelial cells to fibrinogen, von Willebrand factor, and vitronectin yet has no effect on the attachment of these cells to fibronectin, collagen, or laminin. In addition, mAb LM609 inhibits attachment of endothelial cells to an immobilized synthetic peptide containing the Arg-Gly-Asp sequence. This adhesion receptor appears structurally similar to the IIb/IIIa glycoprotein complex expressed on platelets yet is antigenically. distinct, since mAb LM609 fails to recognize IIb/IIIa glycoproteins. This receptor organizes in clusters on endothelial cells during their attachment to von Willebrand factor, vitronectin, or the Arg-Gly-Asp-containing heptapeptide. The data presented in this report suggest that Arg-Gly-Asp recognition may play a significant role in biological events associated with vascular proliferation.

07399126 93043313

Thrombospondin mediates adherence of CD36+ sickle reticulocytes to endothelial cells.

Sugihara K; Sugihara T; Mohandas N; Hebbel RP

Department of Medicine, University of Minnesota Medical School, Minneapolis.

Blood (UNITED STATES) Nov 15 1992, 80 (10) p2634-42, ISSN 0006-4971

Journal Code: A8G

Contract/Grant No.: HL30160, HL, NHLBI; HL31579, HL, NHLBI

Languages: ENGLISH

Document type: JOURNAL ARTICLE

Initiation of vasocclusion in sickle disease pathophysiology may involve abnormal red blood cell (RBC) adhesivity to endothelium, a phenomenon influenced by both RBC and plasma factors. Using human umbilical vein endothelial cells and a gravity sedimentation adherence assay, we have examined thrombospondin (TSP) as a plasma factor in this adhesive event. already-abnormal adherence of sickle RBCs in buffer/albumin is significantly augmented (P < .001) by the addition of TSP, with half-maximal effect at about 0.3 microgram/mL. This effect is abolished by antibodies to either TSP or glycoprotein (GP) IV (CD36), as well as peptides RGDS and CSVTCG. The even greater adherence (P < .005) of sickle RBCs in autologous platelet-rich plasma (without added TSP) is dramatically inhibited by alpha CD36 antibodies (OKM5 and alpha GPIV) and significantly diminished by alpha TSP, by peptides RGDS and CSVTCG, and by two antibodies to the vitronectin receptor (7E3 and LM609). Studies of density-separated subpopulations and of RBC adhesion to immobilized proteins, as well as analysis of sickle RBCs using fluorescence-activated. cell sorting and single cell microfluorometry, show that TSP responsiveness. is a feature of the immature sickle "stress" reticulocytes, which carry ? CD36 (and not GPIIbIIIa-like receptors) as the TSP-receptive moiety. The endothelial cell's participation in this phenomenon appears to be more complex, and the data are consistent with the notion that it involves TSP interaction with other plasma proteins and/or multiple receptor structures. Other potential adhesogenic proteins (plasma von Willebrand factor, vitronectin, fibrinogen, and fibronectin) neither exhibited an affinity for s reticulocytes nor supported increased sickle RBC adherence when added to buffer/albumin in these assay systems. In aggregate, our results indicatethat TSP may be the major promoter of RBC adhesivity in plasma, and they suggest that therapeutic benefit might derive from interference with sickle reticulocyte CD36, as achieved by antibodies and CSVTCG in these studies.

08957750 BIOSIS NO.: 199396109251

Endothelial cell attachment and spreading on human tenascin is mediated by alpha-2-beta-1 and alpha-v-beta-3 integrins.

AUTHOR: Sriramarao P; Mendler Markus; Bourdon Mario A(a)

AUTHOR ADDRESS: (a)La Jolla Inat. Experimental Med., 11077 N. Torrey Pines Rd., La Jolla, CA 92037**USA

JOURNAL: Journal of Cell Science 105 (4):p1001-1012 1993

ISSN: 0021-9533

DOCUMENT TYPE: Article RECORD TYPE: Abstract LANGUAGE: English

ABSTRACT: Human umbilical vein endothelial cells were found to attach and partially spread on human tenascin. The attachment of endothelial cells to tenascin results in elongated cells with interconnecting processes and is distinct from the flattened appearance of endothelial cells on fibronectin, collagen, vitronectin or laminin substrata, suggesting a role for tenascin in modulating cell adhesion and motility. Endothelial attachment to tenascin was partially inhibitable by the SRRGDMS peptide derived from human tenascin and completely inhibitable by anti-integrin antibodies to alpha-2-beta-1 and alpha-V-beta-3. Endothelial cell attachment to tenascin could be inhibited up to 80% with anti-alpha-2 and anti-beta-1 monoclonal antibodies P1E6 and P4C10, respectively, and this was associated with a complete loss in cell spreading. In contrast. pretreatment of endothelial cells with the anti-alpha-V-beta-3 monoclonal antibody LM609, resulted in a 35% inhibition in cell attachment but did not alter cell spreading. In combination the anti-alpha-2 and anti-alpha-v-beta-3 antibodies, could completely abrogate cell spreading and attachment to tenascin-coated surfaces. Affinity purification of 125I labeled endothelial cell extract on a tenascin matrix column followed by immunoprecipitation with monoclonal antibodies to different integrin alpha and beta subunits resulted in the identification of alpha-2-beta-1 and alpha-2-beta-3 integrins, respectively, as tenascin binding receptors. Collagen affinity-purified alpha-v-beta-1 receptor from endothelial cells bound not only to collagen and laminin but also to tenascin in a radio receptor binding assay. The results demonstrate that alpha-2-beta-1 and alpha-V-beta-3 mediate distinct endothelial cell interactions with tenascin; cell spreading and cell binding, respectively. Binding by alpha-V-beta-3 is mediated by the SRRGDMS site on tenascin, whereas the alpha-2-beta-1 binding site remains undefined. The interaction of alpha-2-beta-1 and alpha-V-beta-3 with tenascin may be regulated in a cell type-specific manner as evidenced by the binding of endothelial cell alpha-2-beta-1 and alpha-V-beta-1 to tenascin, and the lack of binding by the same receptors on osteosarcoma

2/7/18 (Item 18 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

09314935 BIOSIS NO.: 199497323305

Adhesive properties of osteopontin: Regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. AUTHOR: Senger Donald R(a); Perruzzi Carole A; Papadopoulos-Sergiou Ageliki; Van De Water Livingston

AUTHOR ADDRESS: (a) Dep. Pathol., Beth Israel Hosp. Harvard Med. Sch., Boston, MA 02215**USA

JOURNAL: Molecular Biology of the Cell 5 (5):p565-574 1994

ISSN: 1059-1524

DOCUMENT TYPE: Article RECORD TYPE: Abstract LANGUAGE: English

ABSTRACT: Osteopontin (OPN) is a secreted adhesive glycoprotein with a functional glycine-arginine-glycine-aspartate-serine (GRGDS) cell-binding domain. An interesting feature of OPN structure is the presence of a thrombin-cleavage site in close proximity to the GRGDS region. Cleavage of OPN by thrombin is likely to be of physiological importance, because cleavage of blood plasma OPN occurs naturally after activation of the blood coagulation pathway. To investigate functional consequences of OPN cleavage by thrombin, cell attachment and spreading assays were performed with uncleaved and cleaved forms of OPN. For all cell lines examined, ફ thrombin-cleaved OPN promoted markedly greater cell attachment and spreading than uncleaved OPN. Cell attachment and spreading on thrombin-cleaved OPN was inhibited both by the soluble GRGDS peptides and an OPN-specific antibody raised to the GRGDS domain of OPN, thus implicating the GRGDS region in mediating the increased cell attachment and spreading observed on thrombin-cleaved OPN. Because the GRGDS sequence in OPN is only six residues from the thrombin-cleavage site, the data suggest the possibility that thrombin cleavage allows greater accessibility of the GRGDS domain to cell surface receptors. To investigate receptors that recognize uncleaved and thrombin-cleaved OPN, affinity chromatography was performed on placental extracts; the cell surface integrin alpha-v-beta-3 bound to columns constructed either with native or thrombin-cleaved OPN and was selectively eluted from each with soluble GRGDS peptide and EDTA. Moreover, adhesion assays performed in the presence of alpha-v-beta-3 blocking monoclonal antibody LM609 identified alpha-v-beta-3 as a major functional receptor for thrombin-cleaved OPN. Several lines of evidence suggest that cleavage of OPN by thrombin occurs in vivo, such as in tumors and at sites of tissue injury, and adhesion assay data presented here indicate that such cleavage is important in the regulation of OPN function.

2/7/19 (Item 19 from file: 5) DIALOG(R)File 5:Biosis Previews(R) (c) 2001 BIOSIS. All rts. reserv.

08740047 BIOSIS NO.: 199395029398

Human melanoma cells derived from lymphatic metastases use integrin alpha-v-beta-3 to adhere to lymph node vitronectin.

AUTHOR: Nip John; Shibata Henry; Loskutoff David J; Cheresh David A; Brodt

Pnina(a)

AUTHOR ADDRESS: (a) Dep. Surgery, Div. Surgical Res., McGill Univ., Donner

Building, 740 Docteur Penfield Ave., Mont**Canada

JOURNAL: Journal of Clinical Investigation 90 (4):p1406-1413 1992

ISSN: 0021-9738

DOCUMENT TYPE: Article RECORD TYPE: Abstract LANGUAGE: English

ABSTRACT: Human melanoma is a highly metastatic cancer and the regional lymph nodes are generally the first site of metastasis. Adhesion to cryostat sections of human lymph nodes was therefore studied using two human melanoma models established from lymph node metastases, namely, MeWo cell lines of diverse metastatic potentials and a highly metastatic cell line of recent origin designated MIM/8. We found a good correlation between the metastatic potentials of the melanoma cells as measured in nude mice and their ability to adhere to cryostat sections of human lymph nodes. When adhesion to immobilized extracellular matrix proteins was measured, a significant increase in adhesion, which correlated with increased **metastasis**, was seen mainly on vitronectin and to a lesser extent on fibronectin. The adhesion to vitronectin and to the frozen sections were specifically blocked by an RGD-containing peptide, mAb 661 to vitronectin and mAb LM609 to integrin alpha-v-beta-3. FACS analysis revealed a significant and specific increase in cell surface expression of alpha-v-beta-3 on the metastatic cells as compared to the parent line. Together these results suggest that the adhesion of melanoma cells to lymph node vitronectin via the alpha-v-beta-3 receptor plays a role in the process of lymphatic dissemination.

2/7/37 (Item 17 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2001 Elsevier Science B.V. All rts. reserv.

05490578 EMBASE No: 1993258677

Endothelial cell attachment and spreading on human tenascin is mediated by alphainf 2betainf 1 and alphavbetainf 3 integrins

Sriramarao P.; Mendler M.; Bourdon M.A.

La Jolla Inst Experimental Medicine, 11077 N Torrey Pines Road, La Jolla, CA 92037 United States

Journal of Cell Science (J. CELL SCI.) (United Kingdom) 1993, 105/4; (1001-1012)

CODEN: JNCSA ISSN: 0021-9533 DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Human umbilical vein endothelial cells were found to attach and partially spread on human tenascin. The attachment of endothelial cells to tenascin results in elongated cells with interconnecting processes and is distinct from the flattened appearance of endothelial cells on fibronectin, collagen, vitronectin or laminin substrata, suggesting a role for tenascin in modulating cell adhesion and motility. Endothelial attachment to tenascin was partially inhibitable by the SRRGDMS peptide derived from human tenascin and completely inhibitable by anti-integrin antibodies to alphainf 2betainf 1 and alphavbetainf 3 Endothelial cell attachment to tenascin could be inhibited up to 80% with anti-alphainf 2 and anti-betainf 1 monoclonal antibodies P1E6 and P4C10, respectively, and this was associated with a complete loss in cell spreading. In contrast, pretreatment of endothelial cells with the anti-alphavbetainf 3 monoclonal antibody LM609, resulted in a 35% inhibition in cell attachment but did not alter cell spreading. In combination the anti-alphainf 2 and anti-alphavbetainf 3 antibodies, could completely abrogate cell spreading and attachment to tenascin-coated surfaces. Affinity purification of sup 1sup 2sup 5I-labeled endothelial cell ex-tract on a tenascin matrix column

followed by immunoprecipitation with monoclonal antibodies to different integrin alpha and beta subunits resulted in the identification of alphainf 2betainf 1 and alphavbetainf 3 integrins, respectively, as tenascin binding receptors. Collagen affinity-purified alphainf 2betainf 1 receptor from endothelial cells bound not only to collagen and laminin but also to tenascin in a radio receptor binding assay. The results demonstrate that alphainf 2betainf 1 and alphavbetainf 3 mediate distinct endothelial cell interactions with tenascin; cell spreading and cell binding, respectively. Binding by alphavbetainf 3 is mediated by the SRRGDMS site on tenascin, whereas the alphainf 2betainf 1 binding site remains undefined. The interaction of alphainf 2betainf 1 and alphavbetainf 3 with tenascin may be regulated in a cell type-specific manner as evidenced by the binding of endothelial cell alphainf 2betal and alphavbetainf 3 to tenascin, and the lack of binding by the same receptors on osteosarcoma MG63 to tenascin.

2/7/38 (Item 18 from file: 73) DIALOG(R) File 73: EMBASE (c) 2001 Elsevier Science B.V. All rts. reserv. EMBASE No: 1992334139 Human melanoma cells derived from lymphatic metastases use integrin alpha(v)betainf 3 to adhere to lymph node vitronectin Nip J.; Shibata H.; Loskutoff D.J.; Cheresh D.A.; Brodt P. Division of Surgical Research, Department of Surgery, McGill University, 740 Docteur Penfield Avenue, Montreal, Que. H3A 1A4 Canada Journal of Clinical Investigation (J. CLIN. INVEST.) (United States) 1992, 90/4 (1406-1413) CODEN: JCINA ISSN: 0021-9738 DOCUMENT TYPE: Journal; Article LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Human melanoma is a highly metastatic cancer and the regional lymph nodes are generally the first site of metastasis. Adhesion to cryostat sections of human lymph nodes was therefore studied using two : human melanoma models established from lymph node metastases, namely, MeWo cell lines of diverse metastatic potentials and a highly metastatic cell_{k} . line of recent origin designated MIM/8. We found a good correlation between the metastatic potentials of the melanoma cells as measured in nude mice and their ability to adhere to cryostat sections of human lymph nodes. When adhesion to immobilized extracellular matrix proteins was measured, a 🤫 significant increase in adhesion, which correlated with increased. metastasis, was seen mainly on vitronectin and to a lesser extent on fibronectin. The adhesion to vitronectin and to the frozen sections were specifically blocked by an RGD- containing peptide, mAb 661 to vitronectin and mAb LM609 to integrin alpha(v)betainf 3. FACS(R) analysis revealed a significant and specific increase in cell surface expression of alpha(v)betainf 3 on the metastatic cells as compared to the parent line. Together these results suggest that the adhesion of melanoma cells to lymph node vitronectin via the alpha(v)betainf 3 receptor plays a role in the process of lymphatic dissemination.

```
2/7/39 (Item 19 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2001 Elsevier Science B.V. All rts. reserv.
```

04524855 EMBASE No: 1991018897

The vitronectin receptor alpha(v)betainf 3 bind fibronectin and acts in concert with alpha\$D5betainf 1 in promoting cellular attachment and spreading on fibronectin

Charo I.F.; Nannizzi L.; Smith J.W.; Cheresh D.A. COR Therapeutics, Inc., South San Francisco, CA 94080 United States Journal of Cell Biology (J. CELL BIOL.) (United States) 1990, 111/6 I (2795-2800)

CODEN: JCLBA ISSN: 0021-9525 DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

The vitronectin receptor (alpha(v)betainf 3) is a member of the integrin superfamily of adhesive protein receptors that mediate a wide spectrum of adhesive cellular interactions, including attachment to vitronectin, von Willebrand factor, fibrinogen, and thrombospondin. We have studied the binding of fibronectin to the purified receptor, and the role of this receptor in the attachment of cells to fibronectin. A solid-phase microtiter assay was developed to investigate the binding properties of the vitronectin receptor. Purified alpha(v)betainf 3 bound fibronectin with high affinity in a saturable, divalent cation-dependent manner. Binding was inhibited by soluble vitronectin, by RGD-containing peptides, and by LM609, a monoclonal antibody against the vitronectin receptor known to inhibit the binding of adhesive proteins to alpha(v) betainf 3. Immunoinhibition experiments showed that M21 human melanoma cells, which express the fibronectin receptor, alpha\$D5betainf 1, as well as alpha(v)betainf 3, used both of these integrins to attach and spread on fibronectin. In support of this finding, M21-L cells, a variant cell line that specifically lacks alpha(v)betainf 3 but expresses alpha(v)beta sup 1, attached and spread poorly on fibronectin. In addition, alpha(v)betainf 3 from surface-labeled M21 cells was retained, and selectively eluted by RGDS from a fibronectin affinity column. These results indicate that alpha(v)betainf 3 acts in concert with alpha\$D5betainf 1 in promoting fibronectin recognition by these cells. We conclude that fibronectin binds to the alpha(v)betainf 3 vitronectin receptor specifically and with high affinity, and that this interaction is biologically relevant in supporting cell adhesion to matrix proteins.